About Probiont
Probiont is a company based in Helsinki (Finland) founded in 2021. It operates as a B2B. Probiont offers products and services including Organ-on-a-Chip Technology. Probiont operates in a competitive market with competitors including CytoSite Bio, Isabl, NovelStem, AccuTheranostics and Precision Therapeutics, among others.
- Headquarter Helsinki, Finland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Probiont Oy
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$33.95 K (USD), Grant
Nov 01, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Probiont
Probiont offers a comprehensive portfolio of products and services, including Organ-on-a-Chip Technology.
Technology for rapid screening of cancer immunotherapy drugs on patient models
Funding Insights of Probiont
Investors in Probiont
Probiont has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Probiont
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Probiont
Investment portfolio details for Probiont
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Probiont
Detailed financials for Probiont
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Probiont Comparisons
Peer comparison for Probiont
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Probiont
Probiont operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CytoSite Bio, Isabl, NovelStem, AccuTheranostics and Precision Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Precision imaging products for immuno-oncology therapy are developed.
|
|
| Locked | Locked | Locked |
Cancer patients' genomes are analyzed by a medical diagnosis platform.
|
|
| Locked | Locked | Locked |
Stem cell diagnostics for predicting cancer chemotherapy resistance are developed.
|
|
| Locked | Locked | Locked |
Personalized chemotherapy response testing is offered for cancer patients.
|
|
| Locked | Locked | Locked |
Precision Therapeutics develops a platform for innovative, personalized cancer therapies.
|
Detailed competitors of Probiont
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Probiont
Complete news archive for Probiont
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Probiont
Probiont was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Probiont is headquartered in Helsinki, Finland.
Probiont focuses on creating personalized solutions for testing the efficacy of cancer immunotherapy. They utilize organ-on-a-chip technology to replicate patient-specific physiological functions, enabling rapid screening of drugs and early identification of effective treatments. This approach supports diagnostics and drug development in oncology. The company is based in Helsinki, Finland, aiming to provide cost-effective tools for targeted therapies without specifying client details.
Probiont's top competitors include CytoSite Bio, NovelStem and Isabl.
Probiont offers Organ-on-a-Chip Technology.
Probiont has 1 investor. Key investors include European Union.